The limited and unequal access for CGP in lung cancer across Europe – Lung Cancer Europe
Oncogene Cancer Research shared a post by Lung Cancer Europe on LinkedIn, adding:
“Not all lung cancers are the same. Advances in precision medicine have given us specific treatments based on certain genetic changes in a tumor – but only if those changes are identified. Comprehensive genetic profiling helps match patients with the most effective, therapies, improving outcomes and quality of life.
Help us raise awareness and be sure to ask about full biomarker testing if you or a loved one is being diagnosed. Knowledge is power.”
Quoting Lung Cancer Europe‘s post:
“Imagine waiting for the right lung cancer treatment – only to find out the right test wasn’t done first.
That’s the reality for too many people with lung cancer in Europe.
Comprehensive Genomic Profiling (CGP) is a single test that can identify key biomarkers for targeted treatment. But access is still limited and unequal.
If we don’t fix this, people will keep missing out on the best treatment options.
The new European Coalition for Comprehensive Genomic Profiling (ECGP) recommendations lay out clear steps to change this.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023